DK1475377T3 - Indol-derivater og deres anvendelse som inhibitorer for phosphodiesterase 4 - Google Patents

Indol-derivater og deres anvendelse som inhibitorer for phosphodiesterase 4

Info

Publication number: DK1475377T3
Authority: DK; Denmark
Prior art keywords: phosphodiesterase; inhibitors; indole derivatives; indole; derivatives
Prior art date: 1998-04-28

Application number

DK04018391T

Other languages

English (en)

Inventor

Hildegard Poppe

Thomas Kronbach

Norbert Hoefgen

Ute Egerland

Degenhard Marx

Stefan Szelenyi

Emmanuel Polymeropoulos

Sabine Heer

Original Assignee

Elbion Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-28

Filing date

1999-04-24

Publication date

2006-10-23

1998-04-28 Priority claimed from DE19818964A external-priority patent/DE19818964A1/de

1999-04-17 Priority claimed from DE1999117504 external-priority patent/DE19917504A1/de

1999-04-24 Application filed by Elbion Ag filed Critical Elbion Ag

2006-10-23 Application granted granted Critical

2006-10-23 Publication of DK1475377T3 publication Critical patent/DK1475377T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Tropical Medicine & Parasitology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Addiction (AREA)
Virology (AREA)
AIDS & HIV (AREA)
Vascular Medicine (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)

DK04018391T 1998-04-28 1999-04-24 Indol-derivater og deres anvendelse som inhibitorer for phosphodiesterase 4 DK1475377T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE19818964A DE19818964A1 (de)	1998-04-28	1998-04-28	Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phospodiesterase 4 und Verfahren zu deren Herstellung
DE1999117504 DE19917504A1 (de)	1999-04-17	1999-04-17	Verwendung von Hydroxyindolen, die Inhibitoren der Phosphodiesterase 4 sind, zur Therapie chronisch obstruktiver Lungenerkrankungen
EP99920779A EP1076657B1 (de)	1998-04-28	1999-04-24	Neue hydroxyindole, deren verwendung als inhibitoren der phosphodiesterase 4 und verfahren zu deren herstellung

Publications (1)

Publication Number	Publication Date
DK1475377T3 true DK1475377T3 (da)	2006-10-23

Family

ID=26045814

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK04018391T DK1475377T3 (da)	1998-04-28	1999-04-24	Indol-derivater og deres anvendelse som inhibitorer for phosphodiesterase 4
DK99920779T DK1076657T3 (da)	1998-04-28	1999-04-24	Hidtil ukendte hydroxyindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK99920779T DK1076657T3 (da)	1998-04-28	1999-04-24	Hidtil ukendte hydroxyindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling

Country Status (27)

Country	Link
US (8)	US6251923B1 (da)
EP (2)	EP1076657B1 (da)
JP (2)	JP3842043B2 (da)
KR (1)	KR100448748B1 (da)
CN (1)	CN1234705C (da)
AR (1)	AR016236A1 (da)
AT (2)	ATE330955T1 (da)
AU (1)	AU748403B2 (da)
BG (1)	BG65023B1 (da)
BR (1)	BR9910029A (da)
CY (1)	CY1105075T1 (da)
CZ (1)	CZ20003985A3 (da)
DE (2)	DE59910142D1 (da)
DK (2)	DK1475377T3 (da)
ES (2)	ES2262072T3 (da)
HU (1)	HUP0101625A3 (da)
IL (2)	IL138847A0 (da)
NO (1)	NO321867B1 (da)
NZ (1)	NZ507406A (da)
PL (1)	PL198983B1 (da)
PT (2)	PT1475377E (da)
SI (2)	SI1475377T1 (da)
SK (1)	SK286192B6 (da)
TR (1)	TR200003130T2 (da)
TW (1)	TW530048B (da)
UA (1)	UA59443C2 (da)
WO (1)	WO1999055696A1 (da)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19946301A1 (de)	1998-04-02	2001-04-19	Asta Medica Ag	Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
DE19814838C2 (de) *	1998-04-02	2001-01-18	Asta Medica Ag	Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
CN1234705C (zh) *	1998-04-28	2006-01-04	埃尔比昂股份公司	新的羟基吲哚、其作为磷酸二酯酶4抑制剂的应用及其制备方法
WO2000067802A1 (en) *	1999-05-10	2000-11-16	Protarga, Inc.	Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
DE19924138A1 (de)	1999-05-26	2000-11-30	Henkel Kgaa	Lösbare Klebeverbindungen
US6469006B1 (en) *	1999-06-15	2002-10-22	Bristol-Myers Squibb Company	Antiviral indoleoxoacetyl piperazine derivatives
TWI269654B (en) *	1999-09-28	2007-01-01	Baxter Healthcare Sa	N-substituted indole-3-glyoxylamide compounds having anti-tumor action
DE19951599A1 (de) *	1999-10-27	2001-05-23	Henkel Kgaa	Verfahren zur adhesiven Trennung von Klebeverbunden
DE19962300A1 (de) *	1999-12-23	2001-06-28	Asta Medica Ag	Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
IT1315267B1 (it) *	1999-12-23	2003-02-03	Novuspharma Spa	Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale
US6436965B1 (en)	2000-03-02	2002-08-20	Merck Frosst Canada & Co.	PDE IV inhibiting amides, compositions and methods of treatment
US6573262B2 (en)	2000-07-10	2003-06-03	Bristol-Myers Sqibb Company	Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives
IT1318641B1 (it)	2000-07-25	2003-08-27	Novuspharma Spa	Ammidi di acidi 2-(1h-indol-3-il)-2-oxo-acetici ad attivita'antitumorale.
DE10037310A1 (de) *	2000-07-28	2002-02-07	Asta Medica Ag	Neue Indolderivate und deren Verwendung als Arzneimittel
DE10037884A1 (de) *	2000-08-03	2002-02-21	Henkel Kgaa	Verfahren zur beschleunigten Klebstoffaushärtung
US6903104B2 (en) *	2001-12-06	2005-06-07	National Health Research Institutes	Indol-3-YL-2-oxoacetamide compounds and methods of use thereof
US7752681B2 (en)	2002-05-24	2010-07-13	Michel Licensing, Inc.	Article of clothing with wicking portion
TW200400177A (en)	2002-06-04	2004-01-01	Wyeth Corp	1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands
UA78999C2 (en) *	2002-06-04	2007-05-10	Wyeth Corp	1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
US20040038958A1 (en) *	2002-07-11	2004-02-26	Chris Rundfeldt	Topical treatment of skin diseases
AU2003255341A1 (en)	2002-08-01	2004-02-23	Elbion Ag	Method for producing highly pure hydroxy indolyl glyoxylic acid amides
UA82323C2 (uk) *	2002-08-09	2008-04-10	Меда Фарма Гмбх & Ко. Кг	Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань
DE10253426B4 (de) *	2002-11-15	2005-09-22	Elbion Ag	Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
DE10318611A1 (de) *	2003-04-24	2004-11-11	Elbion Ag	4-, 6- oder 7-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
DE10318610A1 (de) *	2003-04-24	2004-11-11	Elbion Ag	7-Azaindole und deren Verwendung als Therapeutika
DE10318609A1 (de) *	2003-04-24	2004-11-11	Elbion Ag	5-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
WO2004098578A2 (en) *	2003-05-12	2004-11-18	Altana Pharma Ag	Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
WO2004098606A1 (en) *	2003-05-12	2004-11-18	Altana Pharma Ag	Composition comprising a pde4 inhibitor and shuil-1r ii
US7205299B2 (en) *	2003-06-05	2007-04-17	Zentaris Gmbh	Indole derivatives having an apoptosis-inducing effect
US7211588B2 (en) *	2003-07-25	2007-05-01	Zentaris Gmbh	N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation
US20050187278A1 (en) *	2003-08-28	2005-08-25	Pharmacia Corporation	Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
CN102060806A (zh)	2003-09-11	2011-05-18	iTherX药品公司	细胞因子抑制剂
US20070105937A1 (en) *	2003-12-22	2007-05-10	Miguel Pappolla	Indole-3-propionamide and derivatives thereof
DE102004031538A1 (de) *	2004-06-29	2006-02-09	Baxter International Inc., Deerfield	Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit
WO2006041120A1 (ja) *	2004-10-13	2006-04-20	Kyowa Hakko Kogyo Co., Ltd.	医薬組成物
CA2584169A1 (en) *	2004-10-13	2006-04-20	Kyowa Hakko Kogyo Co., Ltd.	Remedies/preventives for chronic skin disease
WO2006052712A1 (en) *	2004-11-08	2006-05-18	Baxter International Inc.	Nanoparticulate compositions of tubulin inhibitor
TW200738677A (en) *	2005-06-27	2007-10-16	Elbion Ag	Nitro-substituted hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them
EP2258359A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2275095A3 (en)	2005-08-26	2011-08-17	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
AU2006305619A1 (en)	2005-10-19	2007-04-26	Ranbaxy Laboratories Limited	Pharmaceutical compositions of muscarinic receptor antagonists
CA2625153A1 (en)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation of neurogenesis by pde inhibition
CA2625210A1 (en)	2005-10-31	2007-05-10	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
JP2009514969A (ja)	2005-11-09	2009-04-09	コンビナトアールエックスインコーポレーティッド	医学的状態を治療するための方法、組成物、およびキット
AU2007206016A1 (en)	2006-01-13	2007-07-26	Wyeth	Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
US7678808B2 (en)	2006-05-09	2010-03-16	Braincells, Inc.	5 HT receptor mediated neurogenesis
JP2009536669A (ja)	2006-05-09	2009-10-15	ブレインセルス，インコーポレイティド	アンジオテンシン調節による神経新生
CN102772411A (zh)	2006-07-05	2012-11-14	奈科明有限责任公司	用于治疗炎症性肺部疾病的HMG-CoA还原酶抑制剂与磷酸二酯酶4抑制剂的组合
AU2007281747B2 (en) *	2006-08-07	2013-11-07	Ironwood Pharmaceuticals, Inc.	Indole compounds
AU2007292848A1 (en)	2006-09-08	2008-03-13	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
JP2010511041A (ja) *	2006-11-28	2010-04-08	ジオファームオンコロジー，インコーポレイテッド	インジブリンを含むインドリル−３−グリオキシル酸誘導体の癌を処置するための単独またはさらなる薬剤との組み合わせでの使用
EP2125841A1 (en) *	2006-12-13	2009-12-02	Gilead Sciences, Inc.	Monophosphates as mutual prodrugs of anti-inflammatory signal transduction modulators (aistm's) and beta-agonists for the treatment of pulmonary inflammation and bronchoconstriction
US20090182035A1 (en) *	2007-04-11	2009-07-16	Alcon Research, Ltd.	Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
KR20100014565A (ko) *	2007-04-11	2010-02-10	알콘 리서치, 리미티드	알레르기성 비염 및 알레르기성 결막염을 치료하기 위한 ｔｎｆａ의 억제제 및 항히스타민의 용도
US7750027B2 (en) *	2008-01-18	2010-07-06	Oxagen Limited	Compounds having CRTH2 antagonist activity
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
MX2012003693A (es) *	2009-10-01	2012-04-19	Alcon Res Ltd	Composiciones de olopatadine y usos de las mismas.
AR084433A1 (es)	2010-12-22	2013-05-15	Ironwood Pharmaceuticals Inc	Inhibidores de la faah y composiciones farmaceuticas que los contienen
WO2013106547A1 (en)	2012-01-10	2013-07-18	President And Fellows Of Harvard College	Beta-cell replication promoting compounds and methods of their use
GB201407807D0 (en)	2014-05-02	2014-06-18	Atopix Therapeutics Ltd	Polymorphic form
GB201407820D0 (en)	2014-05-02	2014-06-18	Atopix Therapeutics Ltd	Polymorphic form
US20190016680A1 (en)	2016-01-14	2019-01-17	Beth Israel Deaconess Medical Center, Inc.	Mast-cell modulators and uses thereof
MX2021007938A (es)	2018-12-28	2022-01-24	Regeneron Pharma	Tratamiento de trastornos respiratorios con inhibidores de la araquidonato 15-lipooxigenasa (alox15).
US11674450B1 (en)	2021-12-13	2023-06-13	Pratt & Whitney Canada Corp.	System and method for synthesizing engine thrust

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL100127C (da) *	1954-04-28
US2870162A (en)	1954-04-28	1959-01-20	Upjohn Co	Production of certain tryptamines and compounds produced in the process
US2825734A (en)	1955-04-11	1958-03-04	Upjohn Co	Reduction of carbonylic radicals in indolyl-3 compounds
US2930797A (en) *	1957-11-22	1960-03-29	Upjohn Co	2-alkyl-3-indoleglyoxylamides
GB944443A (da)	1959-09-25	1900-01-01
US3028393A (en) *	1960-05-11	1962-04-03	Upjohn Co	Novel 1-(3-indoyl)-1, 2-alkanediols and substituted hydroxymethyl 3-in-dolyl ketones
US3196162A (en)	1961-03-13	1965-07-20	Merck & Co Inc	Indolyl aliphatic acids
US3271416A (en)	1961-10-24	1966-09-06	Merck & Co Inc	Indolyl aliphatic acids
US3259622A (en)	1962-09-07	1966-07-05	Merck & Co Inc	1-benzyl-3-indolyl-alpha-haloalkyl and alkylidenyl acetic acids
US3238215A (en) *	1963-10-17	1966-03-01	Sterling Drug Inc	1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines
US3342834A (en) *	1964-03-02	1967-09-19	Merck & Co Inc	Indolyl alkenoic acids
US3821387A (en)	1965-10-23	1974-06-28	Robins Co Inc A H	The treatment of parkinsonism with 3-(omega-substituted alkyl)-indoles
US3459770A (en) *	1966-12-07	1969-08-05	American Home Prod	Indoleglyoxyloylpyrroles
US3527261A (en)	1968-11-12	1970-09-08	Babcock & Wilcox Co	Tube guide apparatus
US3578669A (en) *	1969-09-16	1971-05-11	Sterling Drug Inc	1-((2 - substituted - 3 - indolyl) - lower-alkanoyl) - cycloalkyl - lower-alkylpiperidines and 1 - ((2 - hydroxymethyl-3 - indolyl)-lower-alkayl)-cycloalkyl-lower-alkylpiperidines
US5192770A (en) *	1990-12-07	1993-03-09	Syntex (U.S.A.) Inc.	Serotonergic alpha-oxoacetamides
JPH08503450A (ja) *	1992-08-06	1996-04-16	ワーナー−ランバート・コンパニー	蛋白チロシンキナーゼを阻害し、かつ抗腫瘍特性を有する２−チオインドール（セレノインドール）および関連ジスルフィド（セレニド）
AU673569B2 (en)	1992-12-02	1996-11-14	Pfizer Inc.	Catechol diethers as selective PDE-IV inhibitors
CA2110095A1 (en) *	1992-12-08	1994-06-09	Teruo Komoto	Arylamide derivatives
US5424329A (en)	1993-08-18	1995-06-13	Warner-Lambert Company	Indole-2-carboxamides as inhibitors of cell adhesion
US5502072A (en)	1993-11-26	1996-03-26	Pfizer Inc.	Substituted oxindoles
US5489586A (en)	1994-03-07	1996-02-06	Warner-Lambert Company	Method for treating inflammatory disease in humans
FI971334A7 (fi)	1994-08-03	1997-04-01	Asta Medica Ag	Indoli-, indatsoli-, pyridopyrroli- ja pyridopyratsolijohdannaiset, jo illa on antiastmaattinen, antiallerginen, anti-inflammatorinen ja immu nomoduloiva vaikutus
DE19511916A1 (de)	1994-08-03	1996-02-08	Asta Medica Ag	Neue N-Benzylindol- und Benzopyrazol-Derivate mit antiasthmatischer, antiallergischer, entzündungshemmender und immunmodulierender Wirkung
US5728844A (en) *	1995-08-29	1998-03-17	Celgene Corporation	Immunotherapeutic agents
TW429148B (en)	1995-10-27	2001-04-11	Pfizer	Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases
CA2258728C (en)	1996-06-19	2011-09-27	Rhone Poulenc Rorer Limited	Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
JP2000516210A (ja)	1996-07-12	2000-12-05	ロイコサイト，インコーポレーテッド	ケモカインレセプターアンタゴニストとその使用方法
AU717430B2 (en)	1996-08-26	2000-03-23	Genetics Institute, Llc	Inhibitors of phospholipase enzymes
DE19636150A1 (de) *	1996-09-06	1998-03-12	Asta Medica Ag	N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
CN1234705C (zh) *	1998-04-28	2006-01-04	埃尔比昂股份公司	新的羟基吲哚、其作为磷酸二酯酶4抑制剂的应用及其制备方法
IT1315267B1 (it)	1999-12-23	2003-02-03	Novuspharma Spa	Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale

1999
- 1999-04-24 CN CNB998079766A patent/CN1234705C/zh not_active Expired - Fee Related
- 1999-04-24 SI SI9930922T patent/SI1475377T1/sl unknown
- 1999-04-24 EP EP99920779A patent/EP1076657B1/de not_active Expired - Lifetime
- 1999-04-24 KR KR10-2000-7011992A patent/KR100448748B1/ko not_active Expired - Fee Related
- 1999-04-24 NZ NZ507406A patent/NZ507406A/xx unknown
- 1999-04-24 PT PT04018391T patent/PT1475377E/pt unknown
- 1999-04-24 BR BR9910029-0A patent/BR9910029A/pt not_active Application Discontinuation
- 1999-04-24 AT AT04018391T patent/ATE330955T1/de not_active IP Right Cessation
- 1999-04-24 DE DE59910142T patent/DE59910142D1/de not_active Expired - Fee Related
- 1999-04-24 SK SK1575-2000A patent/SK286192B6/sk not_active IP Right Cessation
- 1999-04-24 UA UA2000116726A patent/UA59443C2/uk unknown
- 1999-04-24 AU AU38229/99A patent/AU748403B2/en not_active Ceased
- 1999-04-24 DK DK04018391T patent/DK1475377T3/da active
- 1999-04-24 WO PCT/EP1999/002792 patent/WO1999055696A1/de not_active Ceased
- 1999-04-24 EP EP04018391A patent/EP1475377B1/de not_active Expired - Lifetime
- 1999-04-24 DE DE59913617T patent/DE59913617D1/de not_active Expired - Fee Related
- 1999-04-24 CZ CZ20003985A patent/CZ20003985A3/cs unknown
- 1999-04-24 PT PT99920779T patent/PT1076657E/pt unknown
- 1999-04-24 ES ES04018391T patent/ES2262072T3/es not_active Expired - Lifetime
- 1999-04-24 IL IL13884799A patent/IL138847A0/xx active IP Right Grant
- 1999-04-24 DK DK99920779T patent/DK1076657T3/da active
- 1999-04-24 HU HU0101625A patent/HUP0101625A3/hu unknown
- 1999-04-24 AT AT99920779T patent/ATE272631T1/de not_active IP Right Cessation
- 1999-04-24 SI SI9930670T patent/SI1076657T1/xx unknown
- 1999-04-24 TR TR2000/03130T patent/TR200003130T2/xx unknown
- 1999-04-24 ES ES99920779T patent/ES2222706T3/es not_active Expired - Lifetime
- 1999-04-24 JP JP2000545856A patent/JP3842043B2/ja not_active Expired - Fee Related
- 1999-04-24 PL PL343569A patent/PL198983B1/pl unknown
- 1999-04-28 AR ARP990101965A patent/AR016236A1/es active IP Right Grant
- 1999-04-28 US US09/300,973 patent/US6251923B1/en not_active Ceased
- 1999-04-28 TW TW088106886A patent/TW530048B/zh not_active IP Right Cessation
2000
- 2000-10-04 IL IL138847A patent/IL138847A/en not_active IP Right Cessation
- 2000-10-11 BG BG104842A patent/BG65023B1/bg unknown
- 2000-10-27 NO NO20005454A patent/NO321867B1/no unknown
2002
- 2002-02-21 US US10/081,642 patent/US7161009B2/en not_active Expired - Fee Related
- 2002-02-21 US US10/080,821 patent/US6545025B2/en not_active Expired - Fee Related
- 2002-02-21 US US10/081,807 patent/US6602890B2/en not_active Expired - Fee Related
- 2002-02-21 US US10/081,395 patent/US6545158B2/en not_active Expired - Fee Related
- 2002-09-19 US US10/176,435 patent/USRE38624E1/en not_active Expired - Fee Related
2003
- 2003-01-20 US US10/347,659 patent/US6613794B2/en not_active Expired - Fee Related
2004
- 2004-05-27 US US10/856,034 patent/US20040220183A1/en not_active Abandoned
2006
- 2006-03-27 JP JP2006086619A patent/JP2006249091A/ja not_active Withdrawn
- 2006-07-07 CY CY20061100948T patent/CY1105075T1/el unknown

Also Published As

Publication number	Publication date
EP1475377A8 (de)	2005-01-19
US6545158B2 (en)	2003-04-08
DK1076657T3 (da)	2004-11-08
EP1076657A1 (de)	2001-02-21
AU748403B2 (en)	2002-06-06
PL198983B1 (pl)	2008-08-29
BG104842A (en)	2001-10-31
TR200003130T2 (tr)	2001-01-22
BR9910029A (pt)	2000-12-26
TW530048B (en)	2003-05-01
IL138847A0 (en)	2001-10-31
US20020137745A1 (en)	2002-09-26
SK15752000A3 (sk)	2001-08-06
EP1076657B1 (de)	2004-08-04
JP3842043B2 (ja)	2006-11-08
US20020111351A1 (en)	2002-08-15
US7161009B2 (en)	2007-01-09
US20030134876A1 (en)	2003-07-17
NZ507406A (en)	2002-11-26
CZ20003985A3 (cs)	2001-09-12
ES2222706T3 (es)	2005-02-01
US6545025B2 (en)	2003-04-08
US20020119971A1 (en)	2002-08-29
US20040220183A1 (en)	2004-11-04
USRE38624E1 (en)	2004-10-12
BG65023B1 (bg)	2006-12-29
US6251923B1 (en)	2001-06-26
US6613794B2 (en)	2003-09-02
SK286192B6 (sk)	2008-05-06
ES2262072T3 (es)	2006-11-16
CN1234705C (zh)	2006-01-04
NO321867B1 (no)	2006-07-17
CN1307575A (zh)	2001-08-08
PL343569A1 (en)	2001-08-27
EP1475377A1 (de)	2004-11-10
NO20005454L (no)	2000-12-07
US6602890B2 (en)	2003-08-05
JP2006249091A (ja)	2006-09-21
IL138847A (en)	2006-08-20
JP2002513017A (ja)	2002-05-08
HUP0101625A2 (hu)	2001-11-28
KR20010043106A (ko)	2001-05-25
SI1076657T1 (en)	2004-12-31
PT1076657E (pt)	2004-11-30
HUP0101625A3 (en)	2002-12-28
NO20005454D0 (no)	2000-10-27
WO1999055696A1 (de)	1999-11-04
SI1475377T1 (sl)	2006-12-31
AU3822999A (en)	1999-11-16
KR100448748B1 (ko)	2004-09-18
PT1475377E (pt)	2006-11-30
CY1105075T1 (el)	2010-03-03
EP1475377B1 (de)	2006-06-21
ATE272631T1 (de)	2004-08-15
ATE330955T1 (de)	2006-07-15
AR016236A1 (es)	2001-06-20
UA59443C2 (uk)	2003-09-15
DE59913617D1 (de)	2006-08-03
US20020115651A1 (en)	2002-08-22
DE59910142D1 (de)	2004-09-09
HK1035183A1 (en)	2001-11-16

Publication	Publication Date	Title
DK1475377T3 (da)	2006-10-23	Indol-derivater og deres anvendelse som inhibitorer for phosphodiesterase 4
NO986103D0 (no)	1998-12-23	Substituerte indazol-derivater og deres anvendelse som fosfodiesterase (PDE
DK1133477T3 (da)	2004-06-21	Substituerede benzimidazoler og deres anvendelse som parpinhibitorer
DK1000039T3 (da)	2004-08-16	Substituerede quinazolinderivater og anvendelse deraf som tyrosinkinaseinhibitorer
DK0810218T3 (da)	2003-03-24	6-benzyl-2H-pyridazin-3-onderivater samt fremstilling og anvendelsen deraf som inhibitorer af prostaglandin-G/H-syntase I og II (COX I og COX II)
NO20026010D0 (no)	2002-12-13	Substituerte quinazolinderivater og deres anvendelse som inhibitorer
ATE314364T1 (de)	2006-01-15	Heterocyclische natrium/proton- austauschinhibitoren und verfahren
NO992725D0 (no)	1999-06-04	6-Fenylpyridyl-2-amin-derivater anvendelige som NOS-inhibitorer
DK1223933T3 (da)	2007-01-15	5-leddet derivater af heterocyklusser og deres anvendelse som monoaminoxidaseinhibitorer
DK1244647T3 (da)	2006-09-25	Quinzolinderivater som VIGF-inhibitorer
DK1114051T3 (da)	2003-07-14	Inhibitorer for p38
NO20024741D0 (no)	2002-10-02	8-quinolinxantin og 8-isoquinolinxantinderivater som PDE5- inhibitorer
NO984761D0 (no)	1998-10-12	Aminoisokinoliner og aminotienopyridinderivater og deres anvendelse som antiinflammatoriske midler
NO20022125D0 (no)	2002-05-03	Pyrrolderivater som inhibitorer for fosfodiesterase VII
IT1296985B1 (it)	1999-08-03	Derivati benzazinici inibitori della fosfodiesterasi 4
NO20010331D0 (no)	2001-01-19	Ftalazinderivater som fosfodiesterase 4-inhibitorer
NO20003070D0 (no)	2000-06-15	Substituert tiazolidinderivat, fremgangsmÕte for fremstilling og anvendelse derav
FI955661L (fi)	1996-01-19	Substituoidut beta-aryyli- ja beta-heteroaryyli-alfa-syanoakryyliamidijohdannaiset tyrosiinikinaasi-inhibiittoreina
IT1302677B1 (it)	2000-09-29	Derivati benzazinici inibitori della fosfodiesterasi 4
DK0888316T3 (da)	2000-11-27	2-(3H)-oxazolonderivater og deres anvendelse som cox-2 inhibitorer
PL334304A1 (en)	2000-02-14	Derivatives of aromatic amines acting as nos inhibitors
NO20022007L (no)	2002-06-24	Krystaller av et oksyiminoalkansyrederivat og deres anvendelse som antidiabetika
NO20022123D0 (no)	2002-05-03	Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
DK1214302T3 (da)	2004-02-16	Substituerede 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-oner og deres anvendelse som lipasehæmmere
EE200100084A (xx)	2002-08-15	NOS inhibiitorite uued farmatseutilised kasutusv�imalused